{"id":827267,"date":"2025-03-18T16:36:12","date_gmt":"2025-03-18T20:36:12","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"modified":"2025-03-18T16:36:12","modified_gmt":"2025-03-18T20:36:12","slug":"roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","title":{"rendered":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, March  18, 2025  (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.<\/p>\n<p>Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.<\/p>\n<p>\n        <strong>Webcast Details<\/strong><br \/>\n        <br \/>The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Wyjk7AmFwXDAKIbAHhXIHP6UFBrzufsKp2MYRLo5SvggquRdGjLM3WcIu01id4AIBXgeLNiNlruidKMxIEzAOYfBDlbsz6ly2LdI3wp7dR4=\" rel=\"nofollow\" target=\"_blank\">here<\/a> to register for the event. The live webcast will also be available under \u201cEvents &amp; Presentations\u201d in the Investors section of the Roivant website at https:\/\/investor.roivant.com\/news-events\/events. The archived webcast will be available on Roivant\u2019s website after the conference call.<\/p>\n<p>\n        <strong>About Roivant<\/strong><br \/>\n        <br \/>Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant\u2019s pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or \u201cVants\u201d to develop and commercialize our medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. For more information, www.roivant.com.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <u>Investors<\/u><br \/>\n        <br \/>Keyur Parekh<br \/>keyur.parekh@roivant.com<\/p>\n<p>\n        <u>Media<\/u><br \/>\n        <br \/>Stephanie Lee<br \/>stephanie.lee@roivant.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDk0ZWQ4ZmEtNmRiMy00MTRlLTk1MjItNWQ4YmQ3ZGE4YWI2LTEwMzAxODQtMjAyNS0wMy0xOC1lbg==\/tiny\/Roivant-Sciences-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-827267","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; Continue reading &quot;Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T20:36:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\",\"datePublished\":\"2025-03-18T20:36:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"},\"wordCount\":311,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\",\"name\":\"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\",\"datePublished\":\"2025-03-18T20:36:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","og_locale":"en_US","og_type":"article","og_title":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","og_description":"NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) &#8212; Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast will also be available under &hellip; Continue reading \"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-18T20:36:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs","datePublished":"2025-03-18T20:36:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"},"wordCount":311,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/","name":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=","datePublished":"2025-03-18T20:36:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5NjU2OSM2ODEyMzIzIzIwMTg2MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/roivant-to-host-investor-webcast-at-800-am-et-on-wednesday-march-19-to-review-results-from-batoclimab-myasthenia-gravis-mg-and-chronic-inflammatory-demyelinating-polyneuropathy-cidp-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827267","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=827267"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/827267\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=827267"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=827267"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=827267"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}